Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.

Saved in:
Bibliographic Details
Title: Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
Authors: DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Krailo MD; Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA., Glade-Bender J; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Buxton A; Children's Oncology Group Statistics and Data Center, Monrovia, CA., Laack N; Department of Radiation Oncology, Mayo Clinic, Rochester, MN., Randall RL; Department of Orthopedic Surgery, UC Davis Medical Center, Sacramento, CA., Chen HX; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Seibel NL; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Boron M; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Terezakis S; Department of Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN., Hill-Kayser C; Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, PA., Hayes A; Department of Surgery, Howard University College of Medicine, Washington, DC., Reid JM; Department of Oncology, Mayo Clinic, Rochester, MN., Teot L; Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA., Rakheja D; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX., Womer R; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, PA., Arndt C; Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN., Lessnick SL; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH.; The Division of Pediatric Heme/Onc/BMT, The Ohio State University College of Medicine, Columbus, OH., Crompton BD; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA.; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA., Kolb EA; Department of Radiology, Stanford University School of Medicine, Palo Alto, CA., Daldrup-Link H; Department of Radiology, Stanford University School of Medicine, Palo Alto, CA., Eutsler E; Department of Radiology, Washington University School of Medicine, St Louis, MO., Reed DR; Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Gorlick RG; Department of Pediatrics, MD Anderson Cancer Center, Houston, TX.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Apr 10; Vol. 41 (11), pp. 2098-2107. Date of Electronic Publication: 2023 Jan 20.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.22.01815